会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明申请
    • Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascualr disorders
    • 人G蛋白偶联受体及其调节剂用于治疗心血管疾病
    • US20070232519A1
    • 2007-10-04
    • US11604187
    • 2006-11-22
    • John AdamsDaniel Connolly
    • John AdamsDaniel Connolly
    • A61K48/00A01H5/00C12N5/06G01N33/53
    • C07K14/705A01K2217/05A01K2217/075A01K2227/105A01K2227/108A01K2267/0375G01N2333/726G01N2500/10G01N2800/325
    • The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In some embodiments, the GPCR is mammalian, preferably human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gq. In some embodiments, the GPCR increases the intracellular level of inositol 1,4,5-triphosphate (IP3). In some embodiments, a modulator of the GPCR is a modulator of cardiomyocyte hypertrophy. The present invention further relates to methods of using a modulator of the GPCR. Preferred modulators are inverse agonists and antagonists. Inverse agonists and antagonists of the invention are useful as therapeutic agents for the prevention or treatment of heart disease, including hypertrophic cardiomyopathy and congestive heart failure, in particular hypertrophic cardiomyopathy resulting from post-myocardial infarction remodeling, cardiac valve disease, sustained cardiac afterload, myocarditis, and familial hypertrophic cardiomyopathy.
    • 本发明涉及鉴定候选化合物是G蛋白偶联受体(GPCR)的调节剂的方法。 在一些实施方案中,GPCR是哺乳动物,优选人。 在一些实施方案中,GPCR由心肌细胞内源性表达。 在一些实施例中,GPCR耦合到Gq。 在一些实施方案中,GPCR增加1,4,5-三磷酸肌醇(IP3)的细胞内水平。 在一些实施方案中,GPCR的调节剂是心肌细胞肥大的调节剂。 本发明还涉及使用GPCR调制器的方法。 优选的调节剂是反向激动剂和拮抗剂。 本发明的反向激动剂和拮抗剂可用作预防或治疗心脏病,包括肥厚性心肌病和充血性心力衰竭的治疗剂,特别是由心肌梗死后重建,心脏瓣膜疾病,持续的心脏后负荷,心肌炎引起的肥大性心肌病 ,和家族性肥厚型心肌病。